People living with cystic fibrosis in Saskatchewan now have access to an additional treatment option as the province begins covering the cost of a new medication. Starting Aug. 1, coverage for Alyftrek is available to cystic fibrosis patients aged six and older who meet specific medical criteria. The medication is designed for patients with one of 266 rare genetic mutations that cause cystic fibrosis. Related Stories: Study estimates family of four will pay $21,115 for public health care Federal